Journal
ADVANCED HEALTHCARE MATERIALS
Volume 7, Issue 22, Pages -Publisher
WILEY
DOI: 10.1002/adhm.201800830
Keywords
Bi2S3-Tween 20 nanodots; LY294002; mild photothermal therapy; photothermal-resistant; PI3K inhibitors
Funding
- National Basic Research Program of China [2014CB931900, 2016YFA0201600]
- National Natural Science Foundation of China [51772292, 31571015, 11621505, 11435002, 21320102003]
- Key Research Program of Frontier Sciences [QYZDJ-SSW-SLH022]
- Youth Innovation Promotion Association CAS [2013007]
Ask authors/readers for more resources
Although various types of photothermal agents are developed for photothermal cancer therapy, relatively few photothermal agents exhibit high tumor inhibition rate under relatively mild conditions. Herein, a multifunctional Bi2S3-Tween 20 nanoplatform loaded with PI3K inhibitor LY294002 is designed as a novel photothermal agent for inhibitor and photothermal synergistic therapy of tumors under mild photothermal therapy conditions. The LY294002 of PI3K inhibitor, after being loaded by Bi2S3-Tween 20 nanodots, exhibits greatly increased drug utilization and reduced side effects on normal tissues. In vivo, Bi2S3-Tween 20@LY294002 upon near-infrared 808 nm laser irradiation shows potent antitumor activity under relatively mild conditions (power density: 0.6 W cm(-2)). Moreover, the mechanism studies also demonstrate that Bi2S3-Tween 20@LY294002 potently kills LoVo cancer cells under low-power near-infrared light irradiation, by downregulating the expression of heat shock protein 70 (HSP70) so as to increase the sensitivity of tumor cell hyperthermia and activating BAX/BAK-regulated mitochondrial apoptosis pathway. The results demonstrate that the newly synthesized multifunctional nanoplatform paves a new avenue for accurate therapy of photothermal-resistant cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available